Overview

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals